Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Ely

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Blood|June 22, 2012
Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4Xiangao Huang, Maurizio Di Liberto, David Jayabalan, et al.
Cancer Discovery|August 2, 2014
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphomaDavid Chiron, Maurizio Di Liberto, Peter Martin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 13, 2017
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple MyelomaTomer M Mark, Danielle Guarneri, Peter Forsberg, et al.
American Journal of Hematology|August 23, 2021
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myelomaPeter A Forsberg, Adriana C Rossi, Angelique Boyer, et al.
American Journal of Hematology|February 12, 2019
Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myelomaPeter A Forsberg, Adriana C Rossi, Angelique Boyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2011
MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivinTricia Nardiello, Achim A Jungbluth, Anna Mei, et al.
Cancers|August 12, 2022
External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial PracticesInne Nauwelaers, Nele Laudus, Dieter Peeters, et al.
British Journal of Haematology|October 28, 2008
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myelomaTomer Mark, David Jayabalan, Morton Coleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2013
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilizationRuben Niesvizky, Tomer M Mark, Maureen Ward, et al.
Journal for Immunotherapy of Cancer|March 8, 2024
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumorsNikhil I Khushalani, Patrick A Ott, Robert L Ferris, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Blood|June 22, 2012
Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4Xiangao Huang, Maurizio Di Liberto, David Jayabalan, et al.
Cancer Discovery|August 2, 2014
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphomaDavid Chiron, Maurizio Di Liberto, Peter Martin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 13, 2017
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple MyelomaTomer M Mark, Danielle Guarneri, Peter Forsberg, et al.
American Journal of Hematology|August 23, 2021
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myelomaPeter A Forsberg, Adriana C Rossi, Angelique Boyer, et al.
American Journal of Hematology|February 12, 2019
Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myelomaPeter A Forsberg, Adriana C Rossi, Angelique Boyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2011
MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivinTricia Nardiello, Achim A Jungbluth, Anna Mei, et al.
Cancers|August 12, 2022
External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial PracticesInne Nauwelaers, Nele Laudus, Dieter Peeters, et al.
British Journal of Haematology|October 28, 2008
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myelomaTomer Mark, David Jayabalan, Morton Coleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2013
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilizationRuben Niesvizky, Tomer M Mark, Maureen Ward, et al.
Journal for Immunotherapy of Cancer|March 8, 2024
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumorsNikhil I Khushalani, Patrick A Ott, Robert L Ferris, et al.
Pageof 5